While these tumor suppressors are frequently inactivated or downregulated by genetic and epigenetic mechanisms (Zhao et al., 2016; The ICGC/TCGA Pan-Cancer Analysis of Whole Genomes Consortium, 2020; Popov and Gil, 2010), oncogenic ANRIL and P14AS are often overexpressed in many human cancers (Lou et al., 2020; Ma et al., 2020). This evidence concerns the gene CDKN2B-AS1 and cancer.